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SUMMARY 
Gabapentin, originally designed as an antiepileptic drug, has shown promising properties for 
treatment of neuropathic and chronic pain conditions in humans with diseases such as post 
herpetic neuralgia, amyotrophic lateral sclerosis (ALS) and diabetic neuropathy, but the 
evidence regarding analgesic effect, adverse reactions and dosing in animals remains sparse. 
Recommendations in human medicine are to progressively increase, and taper, dosing of 
gabapentin to minimize the risk of adverse effects. The most common adverse effects in humans 
are dizziness, somnolence, peripheral edema and gait disturbance. No studies have been 
conducted on adverse effects of gabapentin in dogs. The pharmacokinetics of gabapentin, in 
both humans and dogs, also suggest dosing three times daily to maintain concentrations 
considered therapeutical in humans.  
A retrospective study of dogs medicated with gabapentin at the University Animal Hospital in 
Uppsala was conducted between 1st of September 2017 and 1st of January 2018. The aim of 
this study was to evaluate the adverse effect profile of gabapentin in dogs. The main research 
hypothesis tested was if there is a dose relationship regarding the adverse effects seen in dogs, 
similar to that seen in humans. An additional hypothesis was if there are risk factors, such as 
not gradually increasing dosing, or peak serum concentrations, for developing adverse effects 
from gabapentin treatment.  
The study was conducted through a questionnaire sent out to owners of dogs medicated with 
gabapentin within the past two years. The first page of the questionnaire included several 
questions with a combination of open- and closed questions. The second part listed adverse 
effects that the owner graded using a 5-grade scale from “not present”, “mild”, “moderate”, 
“severe” to “very severe”. The questionnaire was conducted in Swedish and was sent out by 
mail. 
A total of 50% reported some type of adverse effect during treatment with gabapentin, but 12 
of 16 dogs were, during the whole treatment, on multimodal treatment protocols. Neurological 
adverse effects, similar to those seen in humans on gabapentin treatment, were reported in five 
dogs. These adverse effects could not be related to other medications or disease symptoms. 
Four dogs underwent a period of monotherapy with gabapentin. No adverse effects were 
reported in these dogs. 
Despite recommendations in human medicine to gradually increase the gabapentin dose, only 
4 of 16 dogs were prescribed a dosing regimen following these recommendations. A total of 6 
dogs were administered gabapentin twice daily, whereas the remaining 10 received gabapentin 
3 times daily.  
The study provided insight into dosing and effect of gabapentin in dogs. However, due to a 
small sample size and a relatively homogenous study group regarding dose range, and a large 
number of dogs on multimodal pain treatment, the study resulted in few conclusive findings 
regarding adverse effects of gabapentin in dogs. 
Insufficient knowledge about gabapentin’s properties in dogs and other pets poses a risk that a 
drug that could potentially treat chronic pain conditions may be administered in a way that gives 
results in suboptimal, or not effective, blood concentrations. Therefore, more research is needed 
to determine the pharmacodynamics of gabapentin in dogs. For example, it is of paramount 
importance to further investigate if gabapentin provides the same analgesic effect for dogs as 
seen in studies of humans, as gabapentin may open possibilities of treating otherwise 
untreatable pain conditions. 
SAMMANFATTNING 
Gabapentin utvecklades ursprungligen som en antiepileptisk medicin, men visade sig senare ha 
effekt även vid behandling av neuropatiska och kroniska smärttillstånd hos människa. 
Läkemedlet har använts vid bland annat postherpetisk neuralgi, amylotropisk lateral skleros 
(ALS) och diabetesneuropati, men evidensen gällande analgetisk effekt, biverkingar och 
dosering till djur är i dagsläget begränsad. 
Inom humanmedicinen rekommenderas upptrappning, och nedtrappning, av 
gabapentindosering för att minimera risken för biverkningar. De vanligaste biverkningarna på 
humansidan är yrsel, somnolens, perifera ödem och ataxi. Inga studier på biverkningar av 
gabapentin hos hund finns att tillgå. Gabapentins korta halveringstid talar även för att 
läkemedlet, hos både människa och hund, bör administreras tre gånger dagligen för att bibehålla 
de koncentrationer som visats vara terapeutiska hos människa. 
En retrospektiv enkätstudie av hundar medicinerade med gabapentin vid 
Universitetsdjursjukhuset (UDS) i Uppsala gjordes mellan 1:a september 2017 och 1:a januari 
2018. Målet med denna studie var att undersöka gabapentins biverkningsprofil hos hund och 
om riskfaktorer för att utveckla biverkningar, såsom att ej trappa upp dosen eller höga maximala 
koncentrationer i blod, kunde identifieras. Studiens primära hypotes var att ett dosrelaterat 
samband fanns gällande gabapentins biverkningar hos hund, liknande sambanden som setts på 
humansidan. 
En enkät skickades ut till djurägare med hundar medicinerade med gabapentin inom de senaste 
två åren. Första sidan i enkäten inkluderade flertalet frågor, där en del var öppensvarsfrågor och 
en del flervalsfrågor. Den andra delen i enkäten bestod av en tabell där djurägaren kunde 
gradera biverkningar från “ej förekommit”, ”lindrigt”, ”måttligt”, kraftigt” till ”mycket 
kraftigt”. Enkäten var skriven på svenska och skickades ut via post. 
Hälften av hundarna rapporterade någon form av biverkning under behandling med gabapentin, 
men av dessa stod 12 av 16 hundar under hela behandlingperioden på multimodala 
behandlingsprotokoll. Totalt 5 hundar rapporterade neurologiska biverkningar, liknande de som 
setts vid gabapentinbehandling på humansidan, som inte kunde direkt relateras till individernas 
övriga medicinering eller sjukdomsbild. Totalt 4 hundar behandlades under en period med 
enbart gabapentin. Hos dessa hundar rapporterades inga biverkningar. 
Trots doseringsrekommendationerna på humansidan trappades medicineringen upp hos endast 
4 av 16 hundar. Totalt 6 hundar fick gabapentin två gånger dagligen, medan resterande 10 
medicinerades tre gånger dagligen. 
Studien gav insikt i dos- och effektförhållanden av gabapentin hos hund. Beroende på 
multimodala behandlingsprotokoll och ett begränsat antal svarande och därmed en relativt 
homogen urvalsgrupp avseende dosspann, kan dock få avgörande slutsatser dras från denna 
studie gällande gabapentinbiverkningar hos hund.  
Otillräcklig kunskap om gabapentins egenskaper hos hund, och våra andra husdjur, medför en 
risk att ett läkemedel som skulle kunna behandla kroniska smärttillstånd administreras på ett 
sådant sätt att suboptimala, eller inadekvata, koncentrationer fås. Därför behövs mer forskning 
för att fastställa gabapentins farmakodynamiska profil hos hund. Det är av största vikt att vidare 
kartlägga om gabapentin ger upphov till samma analgetiska effekt hos hund som hos människa, 
då gabapentin potentiellt skulle kunna vara en effektiv behandling av smärttillstånd där andra 
alternativ saknas. 
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INTRODUCTION 
Gabapentin, originally designed as an antiepileptic drug, has, alongside treatment of epilepsy, 
shown promising properties for treatment of neuropathic and chronic pain conditions in humans 
with diseases such as post herpetic neuralgia, amyotrophic lateral sclerosis (ALS) and diabetic 
neuropathy. (FASS, 2017; Thomson/Micromedex, 2006). Several studies on adverse effects in 
humans have proven dizziness, somnolence and peripheral edema to be the most common 
adverse effects of gabapentin (Parsons et al., 2004; Moore et al., 2014). Gabapentin has been 
increasingly used within the veterinary field as an analgesic drug over the past decade. 
However, the evidence regarding analgesic effect, adverse reactions and dosing in animals 
remains sparse (Peck, 2015). 
Although general knowledge regarding epilepsy is somewhat lacking, there are several 
treatment options for dogs, aside from gabapentin, such as phenobarbital, imepitoin, potassium 
bromide, levitiracetam and others (Charalambous et al., 2014). When it comes to chronic and 
neuropathic pain conditions there are limitations in the treatments available (Läkemedelsverket, 
2005) and therefore drugs that can treat these conditions are needed.  
Providing adequate analgesia to animals in pain is key in ensuring animal welfare (Sneddon et 
al., 2014). Opioids and non-steroidal-anti-inflammatory drugs (NSAIDs) both have limitations 
when it comes to chronic pain conditions (Läkemedelsverket, 2005). The development of 
alternative treatment for chronic pain is therefore essential to increase the possibility of treating 
otherwise untreatable pain conditions and thus strengthen the quality of life for pets suffering 
from neuropathic and chronic pain.  
This study aims at  serving as a building block in answering whether gabapentin can be 
classified as a safe drug for dogs and if the adverse effect profile in dogs is similar to that 
described in man. The main research hypothesis was if there is a dose relationship regarding 
the adverse effects seen in dogs, similar to that seen in humans, and if there are risk factors, 
such as not gradually increasing dosing or peak concentrations in blood, for developing adverse 
effects from gabapentin treatment. A retrospective, non-blinded pet owner-directed 
questionnaire with emphasis on adverse effects in dogs treated with gabapentin was created to 
collect information on the properties of the drug in dogs. 
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LITTERATURE REVIEW 
Managing neuropathic pain 
When it comes to neuropathic pain conditions there are limitations in the treatments available. 
The Swedish Medical Products Agency organized a workshop in year 2005 to develop 
recommendations for treatment of pain, including neuropathic pain, in small animals. Non-
steroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, acupuncture and heat treatment 
were recommended for chronic pain conditions in dogs. Alongside NSAIDs and acupuncture, 
corticosteroids were also put forward as an alternative treatment for cats (Läkemedelsverket, 
2005). Pentosan polysulfate (Cartrophen) is also used in dogs for treatment of pain associated 
with osteoarthritis (Ghosh, 1999). Another alternative is tricyclic antidepressants, considered 
first-line agents for neuropathic pain in humans (Moore, 2016). Due to adverse effects and risk 
of cardiovascular mortality (Cohen et al., 2000), they are not used to any larger extent. During 
the previously mentioned workshop, it was stated that available analgesia for chronic pain is 
inadequate (Läkemedelsverket, 2005). Opioids seldom provide the pain relief needed for this 
type of patient and is not optimal for long term use (Läkemedelsverket, 2005). 
Mechanism of action 
Gabapentin is an amino acid originally developed as a structural analogue of the inhibitory 
transmitter substance gamma amino butyric acid (GABA). Because of its similar structure to 
this transmitter substance, gabapentin was thought to be useful in the treatment of epilepsy. 
Gabapentin showed additional properties when used in vivo due to gabapentinoids having an 
alternative mechanism of action (Gee et al., 1996; Field et al., 2004).  
 
Figure 1. A 2D model of the molecular structure of a) gabapentin and b) the endogenous 
signal substance GABA, which gabapentin was constructed as an analogue of (Peck, 2015). 
Research shows that gabapentin has no affinity to GABAA- or GABAB-receptors in rats, 
despite the molecules similarity to the GABA-molecule (Lanneau et al., 2001; Jensen, 2002). 
Gabapentin is not metabolised to GABA. Despite this, gabapentin does increase the 
concentration of GABA in the brain (Kuzniecky et al., 2002). It is not known whether this is 
through increased GABA synthesis, increased release in the vesicles or decreased GABA 
metabolism (KuKanich & Cohen, 2011). 
The currently dominating theory on how gabapentin exerts its effect is that it binds to the α2-δ-
subunits of the voltage dependent calcium channels (VDCC) in the dorsal horn of the bone 
marrow. Several animal studies have strengthened this theory by confirming the significance 
of the α2-δ-subunits role for gabapentins analgesic properties (Gee et al., 1996; Bryans et al., 
1999; Field et al., 2000). There are several different types of voltage-gated calcium channels 
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and a large range of genes encoding their subunits. This, along with co-assembly with a wide 
range of ancillary calcium channel subunits and alternative splicing, give these channels the 
ability to play many different, and very specific, roles in neuronal subtypes. The α2-δ-subunits 
of the VDCC, which gabapentin targets, are upregulated in chronic pain states. Inhibition of 
this passage way, and consequently relief from pain, is therefore achieved by targeting the 
subunit (Zamponi, 2015). The calcium channels are crucial for brain function. When they are 
dysfunctional, neurological disorders such as pain, epilepsy, migraine and ataxia may arise 
(Simms & Zamponi, 2014).  
Gabapentin has been proven to interact with both the α2-δ-1- and the α2-δ-2-subunit of the 
VDCC, but the analgesic properties are linked to interaction with α2-δ-1 (Liao et al., 2010). 
Binding to the VDCC and inhibiting influx of Ca2+ to the neuron decreases the release of 
excitatory neurotransmitters, inhibiting the signaling pathways in the nervous system (Taylor 
et al., 2004). Additionally, Field et al. (2004) has shown that mice with a mutation in the α2-δ-
1-subunit receive no, or very low, analgesic effect of gabapentin.  
There are also studies on acute, inflammatory pain in rat models suggesting antinociceptive 
efficacy of gabapentinoids on pain response. No neuropathic pain component was present in 
the animals in these studies. This forwards the theory that, depending on the type of neuropathic 
pain present, gabapentin may exert its action through more mechanisms than those known to 
date (Liao et al., 2010; Rahman & Dickensson, 2013). 
Indications and administration protocols 
Humans 
According to the Pharmaceutical Specialties in Sweden (FASS), gabapentin has multiple 
indications in human medicine, including treatment of epilepsy, ALS and peripheral 
neuropathic pain. Partial epileptic seizures, with or without generalization, can be treated with 
gabapentin as part of the medical protocol or as monotherapy. As for specific neuropathic pain 
conditions, gabapentin is used in treatment of diabetic neuropathy and post herpetic neuralgia 
(FASS, 2017). The drug is FDA approved in humans for postherpetic neuralgia (PHN) and the 
extended release gabapentin ester formula, Gabapentin Enacarbil, is approved for treatment of 
restless legs syndrome (Thomson/Micromedex, 2006).  
Initial dosing for adults is recommended to start at 300 mg orally on day one, two doses of 300 
mg on day two and three doses of 300 mg on day three. After three days, an increase in the 
separate rations can be done. Maximum dose in adult humans is 1800 mg a day (FASS, 2017). 
The therapeutic concentration of gabapentin in humans is over 2μg/mL 
(Thomson/Micromedex, 2006). Gabapentin is, in Sweden, available in capsules of 100, 300, 
400, 600 and 800 mg (FASS, 2017). At the end of gabapentin treatment, it is recommended that 
the treatment is phased out during a minimum of seven days. This is recommended, regardless 
of indication, as seizures and withdrawal symptoms may occur otherwise (Barrueto et al., 2002; 
See et al., 2011; KuKanich, 2013; FASS, 2017). 
Dogs 
The oral dose needed in dogs to generate the therapeutic plasma concentration seen in man (2 
µg/mL) is 10-20 mg/kg every eight hours. Gabapentin is not approved for use in dogs but is 
frequently prescribed in clinics for a variety of pain related conditions (Vollmer et al., 1986; 
Radulovic et al., 1995; Rhee et al., 2008, KuKanich, 2013). The evidence regarding gabapentin 
as an anti-epileptic drug in dogs is insufficient and therefore it is mainly recommended as an 
alternative adjunctive therapy alongside phenobarbital and potassium bromide in cases of 
treatment failure (Charalambous et al., 2014). 
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Formulas 
Several different formulas of gabapentin have been developed. These include Gabapentin, 
extended release gabapentin (Gabapentin ER) and the prodrug Gabapentin Enacarbil (GEn). 
The three formulations have, in humans, been proven to have different properties when it comes 
to half-life, adverse effects and recommended dose. A large review article has compiled several 
randomized control trials studying dosing of gabapentin for humans suffering from post-
herpetic neuralgia (PHN). In total, the review article includes seven studies with a total of 4091 
randomized individuals, where 2041 of these individuals were studied regarding efficacy and 
2050 individuals were studied with focus on safety assessment of gabapentin. Several formulas 
were used in these studies, including gabapentin, gabapentin ER and GEn. The studies showed 
that single daily oral administration of Gabapentin ER improved pain scoring, but also resulted 
in a higher prevalence of adverse effects, such as dizziness, somnolence and peripheral edema. 
GEn 1200 mg/day and 2400 mg/day was proven to be more effective for treatment of PHN and 
gave rise to fewer adverse effects (Wang & Zhu, 2016). Gabapentin ER and GEn are not 
currently available in Sweden (Fass, 2017). 
Pharmacokinetics 
Gabapentin is in humans distributed to practically all tissues and passes over the blood-brain-
barrier to the central nervous system (Vollmer et al., 1986; Radulovic et al., 1995). The drug 
has been studied in several animal models to evaluate the effect in treatment of epilepsy. In 
these studies, gabapentin has been noted to be quickly absorbed and active after oral 
consumption (Vollmer et al., 1986; Gidal et al., 2000; Kammerer et al., 2011). The oral 
bioavailability in dogs is 80% when administering a dose of 50 mg/kg (Vollmer et al., 1986; 
Radulovic et al. 1995; KuKanich & Cohen, 2011). Radulovic et al. (1995) studied gabapentins 
farmacokinetic profile in one female beagle dog. The dog was administered 50 mg/kg of 
gabapentin intravenously and this was compared to an oral dose of 50 mg/kg in the same dog. 
This study gave a clearance value of 0.1362 L/kg/h, t1/2   of 2.9-4 h and a volume of distribution 
of 0.158 L/kg (Vollmer et al., 1986; Radulovic et al. 1995). 
Gabapentin has a dose-limited absorption behavior and is absorbed from a short part of the 
duodenum. The dose-limited absorption has in man and rat been linked to saturable active 
transporters in the duodenum (Stewart et al., 1993; Larsen et al., 2014). It is not known which 
transporters are involved in absorption. These properties may increase risk for variable, 
unpredictable and suboptimal plasma concentrations (Vollmer et al., 1986; Gidal et al., 2000; 
Kammerer et al., 2011).  
Terminal half-life in dogs after oral administration has been proven to be 3-4 hours. Because of 
this property, gabapentin needs to be administered three times daily to maintain target 
concentration. The target concentration is 2 µg/mL, a concentration which has been derived 
from human medicine due to lack of studies on gabapentins farmacodynamics in veterinary 
medicine (Vollmer et al., 1986; Radulovic et al. 1995; KuKanich et al. 2011; Kukanich & 
Cohen, 2011).  
Studies of the pharmacokinetics of gabapentin in dogs has showed great variation in plasma 
concentrations. In Aghighi et al. (2012) 63 dogs were given an oral dose twice daily. Blood 
samples were collected after 12 and 72 hours from the first dose. The plasma concentrations 12 
hours after oral administration of 10 mg/kg of gabapentin, given twice daily, ranged from >1.0 
μg/mL (detection limit) to 9.08 μg/mL at 24 hours. After 72 hours from the first dose, when 6 
doses had been given, the plasma concentrations ranged from 1.0 μg/mL to 11.00 μg/mL. The 
median concentration was 2.45 μg/mL at 24 hours and 1.36 μg/mL at 72 hours. At 24 hours, 6 
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of 29 dogs given gabapentin fell below the detection limit in serum. The same was true for 7 of 
28 dogs at 72 hours (Aghighi et al., 2012). 
Gabapentin is excreted unmetabolized through the kidney in humans, but this is not the case for 
dogs. On the contrary, when Radulovic et al. (1995) studied the pharmacokinetic profile of 
gabapentin in dogs they reported that 34% of the plasma concentration of gabapentin was 
metabolized to N-methyl-gabapentin in the liver.  
Previous research 
Analgesic properties in dogs 
The evidence base regarding gabapentin’s pain-relieving properties in other species than 
humans is low. Aghighi et al. (2012) showed that 10 mg/kg of gabapentin 2 times daily did not 
increase analgesia, compared with solely opioid analgesia, after intervertebral disc surgery in 
dogs. This was a randomized, placebo-controlled clinical trial with the observer unaware of the 
treatment given. The number individuals included in the study were 63 and they were divided 
into two categories based on serum concentration above or below 3 μg/mL. It is important to 
note that the dogs in this study were administered methadone during the first 24 hours and that 
the dosing was lower than recommended (Thomson/Micromedex, 2006).  
Antiepileptic properties in dogs 
There are no unbiased, well-designed studies on the use of gabapentin in treatment of epilepsy 
in dogs. There are case studies which have shown that, when combined with phenobarbital and 
bromide in dogs, gabapentin has anticonvulsant properties (KuKanich, 2013). A review article 
on the topic mentions two minor studies, which both were considered biased to some extent. 
One of the studies recommend the use of gabapentin as a complementary treatment alongside 
other antiepileptic compounds. One of the studies recommended gabapentin with reservation. 
More studies are needed to conclude the efficacy and safety of gabapentin for treatment of 
epilepsy in dogs (Charalambous et al., 2014).  
Evidence in other species 
Gabapentin has been reported to relieve both traumatic and orthopedic pain in cats (KuKanich, 
2013). However, this information is merely from case reports. Therefore, more studies are 
needed to confirm these results (KuKanich, 2013). No analgesic effect was seen when studying 
the pharmacodynamics of gabapentin in cats in an experimental thermal antinociceptive model 
(Pypendop et al., 2010).  
Gabapentin has been proven to have an acute inhibitory effect on substance P release from small 
primary afferent neurons and effect in inhibiting facilitated pain states after formalin paw 
injections when administered intraperitonally and spinally in rats (Takasusuki & Yaksh, 2011). 
No controlled clinical trials of gabapentin in animals have been conducted on the analgesic 
effects in chronic neuropathic pain. As a result, the appropriate dosing for analgesic effect in 
animals has not been established (KuKanich, 2013). 
Adverse effects 
Gabapentin does not induce CYP450, does not bind to plasma proteins to any larger extent and 
passes through most species bodies unmetabolized, with dogs being the exception. Therefore, 
the substance stands out amongst other anti-epileptic compounds (Radulovic et al., 1995). 
In an article reviewing gabapentin as a potential medication for chronic pain and fibromyalgia 
in adult humans, multiple adverse effects were reported. A total of 62% of the 4125 participants 
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had some adverse effect related to their intake of gabapentin and 11% had to withdraw because 
of these adverse effects (Moore et al., 2014). Several studies on adverse effects in humans have 
proven dizziness, somnolence, peripheral edema and gait disturbance to be the most common 
adverse effects (Parsons et al., 2004; Moore et al., 2014) but a case report also reports a human 
patient presenting with neutropenia when treated with gabapentin (Derbyshire & Martin, 2004). 
The risk for peripheral edema was dose related and seen in individuals given 1800 mg or more 
of gabapentin daily. Dizziness and somnolence were not dose related adverse effects. Serious 
adverse effects did not occur to any higher extent in the gabapentin groups compared to placebo. 
All adverse effects reported in the reviewed articles were linked to a dosage of 1200 mg daily 
or more (Parsons et al., 2004; Moore et al., 2014). Adverse effects of gabapentin in humans 
have been classified as mild to moderate and generally subside within 10 days after day one of 
treatment (Backonja & Glanzman, 2003). Gabapentin is frequently prescribed as part of a 
multimodal pain protocol but there are no studies conducted within the human field on adverse 
effects occurring with multimodal pain treatment, such as paracetamol, NSAIDs or 
glucocorticoids in combination with gabapentinoids (Mathiesen, 2014). 
Another gabapentinoid, pregabalin, has been reviewed in regard to adverse effects. Studies 
show adverse effects of visual disturbances, dizziness and lightheadedness. Despite 
pregabalin’s similar mechanism of action, it has a slightly different adverse effects profile than 
gabapentin. It has been hypothesized that this may be due to their different farmakokinetic 
characteristics or additional mechanisms of action on other receptors, such as NMDA-receptors, 
alpha-2-adrenergic receptors or adenosine A1 receptors that are not yet known (Mathiesen, 
2014). 
Gabapentin is, as noted previously, primarily excreted through the kidney in humans. This may 
give rise to higher serum concentrations of the drug in individuals with impaired kidney 
function, as a result of not excreting the drug to the same extent. This could lead to a higher 
risk of toxic effects on the central nervous system. There are several reports on gabapentin 
induced myoclonus (Zand et al., 2010; Kaufman et al., 2014). Recommendations have been 
made for dose adjustment of gabapentin in humans with renal impairment, where the maximum 
dose with a normal clearance (≥60) is 3600 mg, with clearance 30-60 1400 mg, clearance 15-
30 700 mg and with a clearance of 15 the recommended maximum dose is 300 mg (Schmidt et 
al., 2014). The adjustment schedule of dose due to kidney problems may be less relevant in 
dogs as an alternative elimination pathway has been established. 
In a study of 11 dogs with epilepsy treated with gabapentin, added to a dose regimen of 
previously prescribed phenobarbital and potassium bromide, 6 of 11 showed signs of adverse 
effects. The adverse effects reported were two cases of mild sedation, three cases of sedation 
and one case of ataxia. The serum concentrations varied greatly amongst the individuals with 
signs of adverse effects. Sedation was seen in a golden retriever with a serum concentration of 
2,2 mg/L, where the sample was taken immediately before the next administered treatment 
(Platt et al., 2006). This serum concentration is just above the theoretically therapeutical limit 
(Thomson/Micromedex, 2006). 
Carcinogenic properties  
There is little data on the carcinogenic properties of gabapentin in humans. A cohort study of 
epidemiologic data over 15 years from the United States and United Kingdom showed no link 
between gabapentin and an increased risk for neoplasia, although high doses of gabapentin in 
rats have been related to pancreatic acinar cell tumours (Irizarry et al., 2011). No such research 
has been conducted in dogs.  
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Pregnancy 
Studies in humans have investigated the teratogenic effects of gabapentin during the first 
trimester of pregnancy. A prospective study of 223 pregnant humans treated with gabapentin, 
and an equally sized control group, showed no increased risk for teratogenic effect on the fetus 
when the child bearer was treated with gabapentin. Studies of gabapentins effect on pregnancy 
regarding low birth weight and preterm birth, which have not yet been studied, could give more 
information on the safety of gabapentin (Fujii et al., 2013). 
Withdrawal  
The most common adverse effects of gabapentin in humans are dose related, with a higher risk 
when simultaneously being treated with drugs that have a similar adverse effect profile 
(KuKanich, 2013). Several case reports in humans suggest an increased risk for seizures and 
other withdrawal symptoms when discontinuing gabapentin treatment without tapering the 
dosage (Barrueto et al., 2002; See et al., 2011; KuKanich, 2013). 
Canine specific toxicity 
Because of the metabolization of gabapentin in the canine liver, there is a potential theoretical 
risk for hepatotoxicity if the drug is administered with other liver-straining substances, such as 
phenobarbital (Radulovic et al., 1995; Platt et al., 2006). Some formulas of gabapentin contain 
small amounts of xylitol, which is toxic to dogs, but the amount is considered too small to give 
rise to toxic effects. The combination of these formulas of gabapentin and other xylitol 
containing agents is not recommended (KuKanich, 2013). 
Insensitivity 
Long term gabapentin use could give rise to gabapentin insensitivity. The α2δ-1 subunit is 
crucial for the anti-allodynic effects of gabapentin. In a rat model of central post-stroke pain 
hypersensitivity, it has been shown that the α2δ-1 protein is upregulated during the first two 
weeks after injury. After this time period, the protein is dramatically down regulated. This 
coincided with the emergence of gabapentin insensitivity in these rats (Yang et al., 2016). 
Synergism 
Selective serotonin reuptake inhibitors 
5-HT6 receptor antagonists have been proven to enhance the analgesic effect of gabapentin in 
rats. This, in theory, may provide an option for treatments with lower doses of gabapentin and 
therefore a reduction of the frequency of adverse events (Jayarajan et al., 2015). 
Morphine 
Morphine combined with gabapentin has in man been proven to give a partly superior pain 
elevating effect than the two substances alone. Higher serum concentrations of gabapentin have 
been noted when administered together with morphine. Morphine tolerance and the pain-
relieving properties of this substance in rats has also been improved with co-administration of 
gabapentin. This mechanism has been linked to the increased expression of the anti-
inflammatory cytokine IL-10, which morphine downregulates when gabapentin is not 
administered as part of the treatment. Gabapentin has also reduced early postoperative pain and 
the use of opioids after surgery in humans. The efficacy of the combination of these two 
substances is therefore superior to single therapy with gabapentin or morphine (Eckhardt et al., 
2000; Gilron et al., 2005; Schmidt et al., 2014; Bao, 2014). 
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NSAIDs 
The combination of NSAIDs and gabapentin in rats with inflammatory pain in peripheral nerves 
has given rise to a three times higher pain elevating effect than the sum of the two substances 
effect when administered as single therapy (Picazo et al., 2006). 
Acethylcolinesterase inhibitors 
There is evidence indicating that an increased concentration of acetylcholine in the synapses in 
the CNS in combination with activation of α2-receptors may decrease hypersensitivity from 
neuropathic pain. The use of acetylcholinesterase inhibitors can be used to obtain a higher 
concentration of acetylcholine in synapses (Kimura et al., 2012). Humans diagnosed with 
neuropathic, cancer induced pain have, in a non-blinded study, been treated with a combination 
of gabapentin and acetylcholinesterase inhibitors. The pain-relieving properties were 
significantly higher in these six patients than expected. It should be noted that no comparison 
with placebo was included in this study (Basnet et al., 2014). 
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MATERIALS AND METHODS 
Study design 
A retrospective study of dogs medicated with gabapentin at the University Animal Hospital in 
Uppsala was conducted between 1st of September 2017 and 1st of January 2018. Data was 
collected through a questionnaire sent out to pet owners with dogs medicated with gabapentin 
and from electronic records at the Animal Hospital. 
A questionnaire was designed using the Toronto side effects scale and the UKU Side effects 
rating scale (Lingjærde et al., 1987). Symptoms not seen previously which emerged during the 
two first weeks of treatment with gabapentin were reported. The first page of the questionnaire 
had several questions with a combination of open and closed questions and was followed by a 
second part with a table with a list of adverse effects. Adverse effects were graded based on 
severity, with a scale from 1-5 where 1 was “not present”, 2 was “mild”, 3 was “moderate”, 4 
was “severe” and 5 was “very severe”. The questionnaire was conducted in Swedish. The last 
page included an option to take part of the study when it was complete. The full questionnaire 
is enclosed as an attachment (Appendix 1). 
Study population 
The questionnaire was sent out by mail to households with dogs currently, or previously, on 
gabapentin. The first page of the questionnaire was an introduction that explained the study, 
why the respondent’s answers were important and how long time it would take to finish. It was 
also explained that information the respondents submitted would be presented on group level 
and no personal information would be disclosed. Included in the envelope was a pre-stamped 
envelope with the institution address. An e-mail address for responding by e-mail was also 
provided to improve the respondent rate.  
Inclusion criteria were that the dog had started gabapentin treatment within two years before 
the day they received the questionnaire. All breeds and all indications for use of the drug were 
included. Dogs on multimodal treatment protocols were also included. Dogs who received 
gabapentin within the past 2 years were included in the study. After 3 weeks, a reminder was 
sent out to all non-responders.  
Data collection 
Individuals were identified throught the journal system “Trofast” used at the University Animal 
Hospital in Uppsala. The journal system featured no way to search for individuals who were 
prescribed a particular substance or search for a specific diagnosis. Therefore, the search was 
conducted by going through bookings and posting a list for veterinarians, veterinary technicians 
and students to write down cases if they encountered a dog currently on gabapentin, or one who 
they prescribed gabapentin to. Articles for the literature review were searched for in Pubmed, 
Web of science, Google scholar and Primo. The search words used were: “gabapentin”, 
“neurontin”, “neuropathic pain”, “evidence”, “effect”, “adverse effects”, “side effects”, 
“adverse reactions”, “dog”, “pharmacokinetic”, “pharmacodynamic” and “monte carlo”. 
Information regarding weight, age, dose, reported adverse effects during use and possible 
multimodal therapy was collected from the electronic clinical record. The onset time of adverse 
effects in relation to first day of medication was also noted, as was the consequence on regimen 
of medication after adverse effects were noted. This was done to minimize the risk of 
compliance related misinformation. No veterinary evaluations were conducted, nor any blood 
samples taken, of the animals included in the study.  
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Additionally, the Swedish Medical Products Agency was contacted for access to their database 
on adverse effect reports on gabapentin in dogs. The findings from this database are included 
in the results section. 
Data analysis 
The questionnaires were descriptively evaluated with regard to effect seen when on gabapentin, 
consequences of adverse effects and types of adverse effects seen. Simultaneous treatment with 
medications with a well-documented adverse effects profile and underlying diseases were taken 
into account when evaluating presence of adverse effects. 
A Monte Carlo simulation was designed with data of clearance, volume of distribution and 
bioavailability obtained from Radulovic et al. (1995) and oral dose obtained from the mean 
dose of the dogs included in this study. The Monte Carlo simulation is a stochastic simulation 
model which offers variation in possible outcomes over time (Bonate, 2001). In this study 200 
possible outcomes of the obtained pharmacokinetic data were simulated to show the theoretical 
variance of a single dose of gabapentin. This analysis was performed using Microsoft Excel. 
To test the hypothesis that the risk for adverse effects is lower when gradually increasing initial 
doses were prescribed, two separate groups were created: one where the dogs had progressively 
increased dosing and one where the dogs did not increase dosing. These groups were further 
sub-categorised based on presence of adverse effects. With this table relative risk (RR) for 
adverse effects when not progressively increasing dose could be computed. This was done by 
diving the dogs in groups: one group with dogs who had not progressively increased dosing and 
one where they had progressively increased dosing. They were also separated based on 
prevalence of suspected gabapentin related adverse effects (see Table 3). The 4 dogs on a period 
of single therapy with gabapentin were also evaluated as a separate group. Dosing regimens 
prescribed by veterinarians was compared to recommendations on dosing regimens of 
gabapentin in humans. All RR calculations were done manually by the author of this paper. No 
conflict of interest or biased evaluators partook in this study. 
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RESULTS 
Out of the 43 questionnaires sent out, 17 households answered the questionnaire. One of the 
questionnaires sent back contained no information and was excluded from the study. The final 
count of dogs included in the study was 16, which gave a response rate of 39.5%. 
All but one of the dogs included in the study were treated with gabapentin because of pain 
related pathology. One dog came to the clinic because of unprovoked aggression. The main 
theory for this dogs’ behavior was pain or epilepsy.  
Four dogs experienced a period of monotherapy with gabapentin, apart from one dog being 
administered a previous single dose of Nexgard. Twelve dogs received multimodal treatment 
protocols. The most common drugs prescribed alongside gabapentin included NSAIDs, 
corticosteroids and opioid analgesics. One dog was given gastroprotective medication and one 
dog was on allergen specific immunotherapy (Artuvetrin). 
Doses of gabapentin ranged between 15.2 mg/kg to 45.4 mg/kg every 24 hours. No correlation 
was seen between single therapy and higher doses of gabapentin. The doses of gabapentin were 
divided into three rations daily in ten dogs, and six dogs were prescribed administration twice 
daily. A total of four dogs were prescribed a dosing regimen of gabapentin which was initially 
progressively increased, and twelve dogs did not progressively increase the dosage when 
starting gabapentin. The mean oral dose was 11.2 mg/kg every 8-12 hours. As noted previously, 
an oral dose of 10 mg/kg every 8 hours is needed in most dogs to obtain the recommended 
serum concentration of over 2 µg/mL (Radulovic et al., 1995). The relevance of this 
recommendation is delineated in the Monte Carlo simulation of gabapentins pharmacokinetic 
profile in Figure 2 below as it shows that all dogs had a serum concentration >2 µg/mL after 8 
hours, whereas most had < 2µg/mL at 12 hours after last dose, and all after 12.8 hours. 
Figure 2. Monte Carlo simulation of the kinetic profile of orally administered gabapentin in 200 dogs. 
Clearance: 0.1362 L/kg/h, Volume of distribution: 0.158 L/kg, Bioavailability: 80% extrapolated from 
Radulovic et al. (1995). The variation of these parameters was set to 0%. Variation in absorption was 
set to an estimated 20% based on gabapentins dose limited absorption (Stewart et al., 1993; Larsen et 
al., 2014). The oral dose was obtained from the mean dose of the dogs included in this study and 
therefore set to 11.2 mg/kg. Cmax in this simulation was around 10 μg/mL. All dogs were below the 
theoretical terapeutical limit 2 μg/mL (Thomson/Micromedex, 2006) between 8 and 12.8 hours after 
administration.  
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A total of 50% (8/16) reported any type of adverse effect during treatment with gabapentin. 
Many of these dogs had adverse effects that could be related to other substances included in 
their therapy, such as polyuria/polydipsia and weight gain seen when on gabapentin combined 
with corticosteroids. Neurological adverse effects were reported in five dogs. These adverse 
effects were similar to those seen in humans on gabapentin treatment (KuKanich, 2013) and 
could not be related to other medications or disease symptoms.  
Figure 3. All reported adverse effects in the submitted questionnaires with staging of severity included. 
Symptoms translated from Swedish questionnaire to English. Dogs on multimodal treatment protocols 
included. 
 
Of the 16 households who answered the study, 15 had a dog who, at some point, received 
multimodal treatment. Of these 14 dogs two only received multimodal treatment during a short 
period of time and could be classified as “single therapy” cases. One of the dogs was given one 
tablet of Nexgard before gabapentin treatment. This dog was also classified as “monotherapy”. 
This resulted in a total of four dogs who could be evaluated in regard to gabapentin as single 
therapy. In the group of four dogs on a period of single therapy with gabapentin no adverse 
effects were seen. 
Dose regimens varied between two and three doses per day, where six dogs were administered 
gabapentin two times daily and ten dogs three times daily. Five of six households with dogs 
prescribed gabapentin two times daily reported no adverse effects and one household answered 
this question inconclusively. Three of these dogs were on a period of single therapy with 
gabapentin and five of six reported improvement of gabapentin therapy. One household did not 
answer this question. 
The adverse effects reported generally occurred at the beginning of gabapentin treatment. The 
definition of “beginning of gabapentin treatment” was not stated (see Appendix 1). One owner 
reported withdrawal symptoms, adverse effects at the end of gabapentin treatment, which has 
also been identified as a risk in humans (Barrueto et al., 2002; See et al., 2011; KuKanich, 2013; 
FASS, 2017). A total of two of 16 dogs (12.5%) had to withdraw from gabapentin treatment 
because of adverse effects. Both of these dogs had adverse effects that occurred at the start of 
gabapentin treatment and reportedly became depressed when on gabapentin. 
  
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total reported adverse effects
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Table 1. Table presenting the progressive increase in dose, prevalence of adverse effects, pet owners’ 
perception of efficacy, additional medication administered, and which dogs presented with adverse 
effects that could not be directly related to other medication or pathology of disease. Information 
obtained from questionnaire answers and journals including 16 dogs treated with gabapentin. 
Case Progressive 
increase 
Adverse 
effects 
Perceived as 
helped 
Additional medication Adverse effects 
most likely due to 
gabapentin 
1 No No Yes NSAID + 
gastroprotective 
medication 
No 
2 No No Yes, mildly Tramadol, cortisone, then  
swiched to NSAID 
No 
3 Yes Yes First time yes, 
second time no 
Initially NSAID, then  
switched to cortisone 
Yes 
4 No Inconclusive Yes Cortisone + allergen 
treatment 
No 
5 No No Yes Cortisone No 
6 No Yes No, depressed 
from gabapentin 
NSAID Yes 
7 No Yes No, depressed 
from gabapentin 
NSAID Yes 
8 No Yes Yes NSAID + opioid No 
9 No Inconclusive Yes Opioid + cortisone No 
10 Yes Yes  Yes, markedly  Cortisone Yes 
11 No No Yes, partly A few days on NSAID, 
then  
just gabapentin. 
No 
12 No No - One tablet of Nexgard 
previously 
No 
13 Yes No Yes A few days on NSAID, 
then  
just gabapentin. 
No 
14 No Yes Yes Initial opioid + Cortisone Yes 
15 Yes No Yes NSAID No 
16 No No Yes No No 
 
A total of ten dogs were reportedly markedly improved by their treatment, three reported being 
partially improved and one respondent did not answer this question. Two dogs were not 
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perceived as helped by their owners. One of these dogs was on a dose of 9.1 mg/kg three times 
daily and the other dog on 13.2 mg/kg three times daily. They were both, as previously 
mentioned, reportedly depressed from gabapentin and had to withdraw from treatment. These 
two dogs had not progressively increased their dosage. In the group of four dogs who had a 
period of single therapy with gabapentin two pet owners reported their dogs’ conditions as 
improved, one partly improved, and one pet owner did not answer this question. 
Of the dogs included five weighed <10 kg and eleven dogs weighed >10 kg. Of the dogs <10 
kg one of five were administered gabapentin two times daily and four of five three times daily. 
The mean total dose for dogs <10 kg was 37.9 mg/kg per 24 hours. Of the dogs >10 kg five of 
eleven were administered gabapentin two times daily and six of eleven three times daily. The 
mean dose for this group was 25,1 mg/kg every 24 hours. In the group of dogs <10 kg two of 
five had adverse effects that were classified as being most likely related to gabapentin. The 
same was true for three of five dogs in the >10 kg group. The relative risk (RR) for adverse 
effects in dogs <10 kg was calculated to 1.47 and the P-value was 0.60. 
Table 2. Table over dogs divided into groups based on weight (over/under 10 kg), daily dosing 
intervals and separate rations, total dose per kilo every 24 hours and if the dog at some point received 
single therapy of gabapentin. 
 
As previously noted, there were five questionnaire answers which indicated adverse effects that 
could not be related to underlying disease or other medication given. A separate calculation, 
only including these adverse effects when studying the risk factors for adverse effects, was 
conducted. This was done to rule out bias related to additional drugs. The RR for adverse effects 
when not progressively increasing initial dosage of gabapentin was 0.5 (P-value: P = 0.33), see 
table 3.  
 
Case 
Dog over/ 
under 10 kg Dose/kg  
Total dose/ kg 
q24 hours 
Single therapy  
at some point 
1 Over 12.05 mg x2 24.1 mg/kg No 
2 Over 8.55 mg x3 25.65 mg/kg No 
3 Over 9.84 mg x3 29.52 mg/kg No 
4 Under 22.7 mg x2 45.4 mg/kg No 
5 Under 12.66 mg x3 37.98 mg/kg No 
6 Under 13.16 mg x3 39.48 mg/kg No 
7 Over 9.09 mg x3 27.27 mg/kg No 
8 Under 10.53 mg x3 31.59 mg/kg No 
9 Over 11.3 mg x3 33.9 mg/kg No 
10 Over 9.43 mg x3 28.29 mg/kg No 
11 Over 10 mg x3 30 mg/kg Yes 
12 Over 13.45 mg x2 26.9 mg/kg Yes 
13 Over 9.09 mg x2 18.18 mg/kg Yes 
14 Under 11.76 mg x3 35.28 mg/kg No 
15 Over 8.47 mg x2 16.94 mg/kg No 
16 Over 7.58 mg x2 15.16 mg/kg Yes 
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Table 3. Presence of adverse effects related to progressive increase of initial dosing of gabapentin. 
Individuals with adverse effects most likely related to other medication or symptoms of disease marked 
as “no adverse effect”. 
 
Adverse effect No adverse effect Total 
 
No progressive increase 
in dose 
3 9 12 
 
Progressive increase 
in dose 
2 2 4 
 
Total 
 
RR: 0,5 
5 
 
 
11 16 
 
 
The Swedish Medical Products Agency reported a total of three adverse effect reports on 
gabapentin use in dogs between January 2010 to November 2017. The reports included two 
Cavalier King Charles Spaniels and one Rottweiler. One of the Cavalier King Charles Spaniel’s 
reportedly had tongue disorder and tiredness during gabapentin use, one suffered from 
pancreatitis and was euthanized, and the Rottweiler presented with aggression. 
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DISCUSSION 
This study was conducted to increase the knowledge about gabapentin in our pets. A large 
amount of the information on gabapentin’s pharmacodynamics and adverse effects in animals 
is to date comprised of case reports.  
It is important to note that the overall number of dogs treated with gabapentin, and thus included 
in the study, is relatively small. The information obtained is solely based on pet owner 
observation and several of the individuals in the study have been on multimodal pain relief 
protocols. Inclusion of animals on multimodal treatment protocols is not optimal and makes 
interpretation of results more difficult, but because of the low number of cases treated with 
solely gabapentin the sample size of these animals would have been minimal.  
Questionnaire 
Questionnaire design 
The questionnaire sent out to pet owners was, as mentioned in “Materials and Methods”, 
conducted with inspiration from the UKU- and Toronto side effects scales. These two scales 
are used within human medicine, mainly when studying the adverse effects related to 
psychotropic drugs (Lingjærde et al, 1987; Vanderkooy et al., 2002). The final questionnaire 
included parts of these scales but was modified to include a broader spectrum of adverse effects 
and become more suited for evaluations of animals. Options that were defined by a certain 
sensation or feeling were modified to describe a sign or symptom a practitioner or pet owner 
could observe in the animal studied.  
The questionnaire design provided postal service or e-mail as the two options for responding. 
The strengths of these methods, compared to face-to-face or telephone-interviews, lie in the 
opportunity for pet owners to reflect over their answers during several days before responding 
and the researchers not having to book a specific time to connect with the respondents. There 
is no risk for the interviewer to influence answers or for the interviewer to avoid sensitive 
questions. Negative aspects of this type of design could be that the respondents have no 
opportunity to ask follow-up questions, misconceptions cannot be explained and nuances in 
answers may be overlooked (Lina Hedman, 20171).  
Study Design 
Questionnaires are efficient in retrieving data for studies and have additional advantages 
including standardization of questions and that they are easy to use. However, the questionnaire 
gives rise to several potential sources of bias, especially because of the answer frequency being 
low. A questionnaire study based solely on pet owner observation may lead to observational 
bias such as false reports of adverse effects and inconspicuous adverse effects being overseen. 
The people who decide to answer the questionnaire may of some reason be more prone to 
answering, and therefore a low response rate affects the degree of how representative the 
findings are. For example, pet owners who saw adverse effects in their dogs, may be more 
invested in the subject matter and therefore these dogs may be overrepresented in the study.  
The base for inclusion criteria was broad due to the small number of individuals treated as well 
as dogs on gabapentin as single therapy strenuous to find. A retrospective design would have 
benefitted from a shorter time span of inclusion to limit recall bias for events further back in 
time, but this would have resulted in a smaller sample size. A broad inclusion criterion, in this 
                                                 
1 Lina Hedman, Institutet for Bostads-och Urbanforskning, 2017-12-05 
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case, limits the number of conclusions that can be drawn from the study and requires a more 
descriptive approach. 
Results 
The respondent rate was 39.5%, which is classified as an acceptable respondent rate (Lina 
Hedman, 20172). The recommended minimum number of cases to include in a randomized 
selection questionnaire study for representative results is 30 (Lina Hedman, 2017 3). This 
questionnaire was, as previously noted, not randomized as all individuals identified to meet the 
inclusion criteria were included.  
If all questionnaires had been answered the total number of individuals with a period of solely 
gabapentin treatment would have been eleven and the span of doses broader. This could have 
contributed to more information on the specific adverse effect profile of gabapentin. Only four 
respondents were included who at some point were prescribed gabapentin as single treatment 
and the study group was relatively homogenous in respect to dose variation. These factors 
significantly impact the bearing of the results as they may not be representative for the 
population at large. Therefore, caution should be taken in drawing conclusions from the results 
to a wider population, in particular since the statistical test for the RR was non-significant. Even 
if the RR for adverse effects was higher in the small dog group and in the group who 
progressively increased dosing thus opposing the expectations, these results do not conclude 
these factors as risk factors for adverse events. 
In the group of dogs on a period of single therapy with gabapentin, including four dogs, no 
adverse effects were seen. Even if this sample is too small to calculate RR on, it is an interesting 
finding that none of the dogs on single therapy with gabapentin presented with adverse effects. 
This could be a coincidental finding, or an indication that gabapentin is in fact a relatively safe 
drug in dogs. It leaves to question how many of the reported adverse effects in this study are in 
fact true adverse effects of gabapentin.  
The improvement on gabapentin treatment reported by pet owners may be due to gabapentin 
treatment, but could also be an effect of other medications, rest, a physical therapist, placebo 
effect or a spontaneous improvement. Out of the four pet owners with dogs on single therapy 
with gabapentin three reported improvement with treatment. This rules out other medications 
as the reason for improvement and may indicate that the dose prescribed to these dogs was 
therapeutic, but the other bias factors mentioned above still may be the reason for improvement 
in these dogs. Five of six dogs who were prescribed gabapentin twice daily also reported 
improvement on gabapentin treatment. Three of these dogs were on a period of single therapy 
with gabapentin. This gives rise to a possibility that gabapentin treatment twice daily may be 
sufficient for controlling neuropathic pain conditions in dogs. Because of these findings, and 
the lack of previous research, controlled clinical trials of the pharmacodynamics of gabapentin 
are needed to establish a therapeutic dose and dose interval. It is also important to note that pet 
owners, and no trained professionals with evaluation protocols, have subjectively evaluated 
these dogs’ improvement. In future studies, ideally trained staff would evaluate the dogs in a 
blinded study design although changes at home over time might need additional technical 
solutions such as activity necklace, filming, etcetera to capture any changes in the dogs’ status. 
Many of the dogs with reported adverse effects had adverse effects that could be related to other 
substances included in their therapy, such as polyuria/polydipsia and weight gain seen when on 
gabapentin and corticosteroids. These adverse effects are well known and confirmed adverse 
                                                 
2 Lina Hedman, Institutet for Bostads-och Urbanforskning, 2017-12-05 
3 Lina Hedman, Institutet for Bostads-och Urbanforskning, 2017-12-05 
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effects of corticosteroids.  Because of this, five cases with reported adverse effects were selected 
into a separate group. This was done because of the character of these adverse being similar to 
those seen in humans, such as somnolence and other signs of central nervous impact. These 
dogs were not on other medication with known side effects of this character or affected by 
disease that would be expected to give rise to these signs. It was done to rule out false positive 
reports of adverse effects. Despite this, it cannot be certainly established that these adverse 
effects were from gabapentin, and in some cases true adverse effects might have been overseen, 
and therefore result in an overrepresentation of false negative results. 
The two dogs who were reportedly depressed and did not improve from gabapentin treatment 
had not progressively increased dosing, but they were on dosing three times daily and on the 
lower dose interval (9.09-13.16 mg/kg). Due to the limited scope of this study no blood samples 
were taken of the animals included. This could theoretically have been a way to correlate blood 
concentrations of gabapentin to adverse effects, as gabapentin has been proven to give rise to a 
broad spectrum of serum concentrations at similar oral doses. Fluctuations in gabapentin 
concentrations could also be evaluated with blood concentrations measured. This could be used 
to investigate if different adverse effects were dose dependent in dogs, and if fluctuations 
impacted on the risk for developing adverse effects. Because of the lack of blood samples, it 
cannot be known if these two dogs had higher serum concentrations. The reason for adverse 
effects in these dogs could therefore not be thoroughly investigated and are consequently not 
established. Future studies within this field should aim at correlating serum concentrations with 
adverse effects and include veterinary evaluations of the animals. 
The information on adverse effects obtained from the Swedish Medical Products agency is 
scarce. Only three reports on adverse effects from gabapentin have been sent in since 2010. 
This may be due to a low frequency of adverse effects, but more likely it reflects a low report 
rate of adverse effects within the veterinary field in Sweden. The three reports sent in included 
tongue disorder, tiredness, pancreatitis and aggression. Similar to the reasoning above, it is not 
known whether these reports reflect true adverse effects of gabapentin. They may be related to 
underlying disease, other medication or a coincidentally occurring pathology. Hence, no 
conclusions of the side effects in gabapentin treated dogs in Sweden can be drawn from this 
information. 
Despite the recommendation in human medicine to progressively increase, and taper, the dose 
of gabapentin, only four of 16 dogs were prescribed a dosing regimen including progressive 
increase of gabapentin by their veterinarians. In addition, not all dogs received the 
recommended dosing regimen of three times daily but six dogs also received dosing twice daily. 
All but one of these dogs weighed over 10 kg and the separate doses were not significantly 
higher than doses for dogs who received three rations a day, which excludes tablet sizes being 
too large for small dogs as the reason for twice daily dosing. As the adverse effects and optimal 
therapeutic dose of gabapentin in dogs has not been investigated previously broader knowledge 
amongst veterinarians on how to optimally administer this drug should be a goal within the 
field. This could potentially contribute to a reduction of adverse effects and, in cases with 
suboptimal plasma concentrations, prohibit gabapentin from being ruled out on the basis of 
default of treatment response. 
Pharmacokinetics 
All available formulations of gabapentin are oral formulations, which makes true bioavailability 
and volume of distribution impossible to establish. All studies, but one, on bioavailability in 
animals are to date conducted with oral administration of gabapentin. These pharmacokinetic 
properties can only be studied with an intravenous formulation. Vollmer et al. (1986) study, 
19 
 
with intravenous gabapentin, does not present any figures on clearance or volume of 
distribution. 
Terminal half-life in dogs after oral administration has been proven to be 3-4 hours and the 
theoretical therapeutic concentration is 2µg/ml. To obtain concentrations over this limit for >12 
hours with a half-life of 3 hours (four half-lives) a Cmax of 32 µg/ml is needed. This would 
require large single doses, which consequently would result in large fluctuations of the 
gabapentin concentration in blood. Because of this property, gabapentin needs to be 
administered three times daily to maintain target concentration. Dosing three times daily could 
give rise to non-compliance in our pets. In epilepsy patients, this could be a substantial risk. A 
sustained release formula for our pets could therefore be an alternative to bypass this risk. There 
are no studies on extended release gabapentin in dog, and therefore the plasma concentration 
and half-life following administration of gabapentin enacarbil is not known (KuKanich & 
Cohen, 2011). Future research on the pharmacokinetics of an extended release formulation 
could, in theory, improve pet owner compliance and reduce the risk of peak drug levels, or 
fluctuations, inducing adverse effects. 
Previous studies have seen an ample difference in dogs, compared to other species, regarding 
the metabolism of gabapentin. In dogs, approximately 34% of the compound is metabolized to 
N-methyl-gabapentin. The properties of this metabolite have not been studied to date, but 
metabolism has not been seen in any other species studied. Gabapentin is considered a relatively 
safe drug in humans because of not binding to plasma proteins and not being metabolized in 
the liver, but with these variations in metabolism, humans are not an optimal model for studying 
gabapentin in dogs. Further, there is no information to be found on the metabolites protein-
binding properties and risks related to this factor. The results Radulovic et al. (1995) presented 
show that species variations exist. This is one additional reason why extrapolation from human 
medicine regarding dosing, efficacy and safety may pose a risk for dogs when medicating with 
gabapentin. Investigation of the role of this metabolite could give more information on the 
dimension of the risks, or potential benefits, gained from the metabolization.  
Previous research 
In Aghighi et al. (2012), where 63 dogs were administered 10 mg/kg of gabapentin twice daily 
no difference was seen between the gabapentin group and placebo. The dose given in this study 
was slightly lower than recommended (Thomson/Micromedex, 2006; Aghighi et al., 2012), 
which could be a possible explanation for the outcome, but whether this was related to the low 
dosing used in the study or gabapentins analgesic profile, which does not include acute 
inflammatory pain, is not known (Aghighi et al., 2012).  
Several studies included have administered relatively low doses of gabapentin and taken blood 
samples from the dogs 12 hours after administration (Platt et al., 2006; Aghighi et al., 2012). 
Despite this the serum concentrations at these points have been higher than seen in other studies 
where administered doses were higher and blood samples taken closer to the point of 
administration (Vollmer et al., 1986; Radulovic et al., 1995; Rhee et al., 2008). One reason for 
this could be that gabapentins dose-limited absorption gives rise to lower oral bioavailability at 
the higher doses administered (Stewart et al., 1993; Larsen et al., 2014). Variations may also 
exist in the way of measuring blood concentrations of gabapentin. Further, it is not known if 
the metabolite, N-methyl-gabapentin, is included in the measurements made in the separate 
studies. In Aghighi et al. (2012) study one dog reaches a confounding 11.00 µg/mL at 72 hours, 
12 hours after oral administration of 10 mg/kg of gabapentin. This serum concentration is higher 
than the expected Cmax obtained from that dose, which, according to KuKanich (2013), is 
approximately 10 µg/mL.  
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Sedation has been reported in a golden retriever with a serum concentration just above the 
theoretical therapeutic limit (Platt et al., 2006; Thomson/Micromedex, 2006), which could be 
an indication that some adverse effects are not dose related in dogs. However, it is important to 
note how long after administration blood samples are collected. In this case the sample was 
taken immediately before the next administered treatment (Platt et al., 2006) and the Cmax in 
this dog is not known. It can therefore not be concluded if this dog had a high gabapentin 
concentration in blood before the blood sample was taken. Conclusively no conclusions can be 
drawn regarding the dose relationship of the adverse effect seen in this dog. 
Set apart from the known mechanisms of action that gabapentin has there is evidence pointing 
towards the fact that gabapentin has several other mechanisms of action that are unknown (Liao 
et al., 2010). They suggest that gabapentin could exert its effect in several different ways 
depending on the type of neuropathic pain present. More research is needed to establish the 
alternative mechanisms of action for gabapentin and the pharmacodynamic properties these 
mechanisms may have. 
Studying gabapentin 
As noted, the substance is often used as a complementary drug in a multimodal protocol for 
controlling pain or epilepsy, which complicates distinguishing any adverse effects from 
gabapentin, from other drugs or the combination of them. Despite gabapentin being frequently 
used in multimodal pain protocols there are no controlled clinical trials in humans on the 
adverse effects occurring in combination with the most common pain medications, such as 
opioids or NSAIDs (Mathiesen, 2014). With metabolisation occurring in dogs, the significance 
of the combination of drugs could be higher in this species. A combination of several liver 
straining drugs, such as the combination with phenobarbital, could theoretically impact 
negatively on the liver as the combination of drugs with adverse effects affecting the same 
organ, or enzyme, could contribute to accumulation of adverse effects.  
Studies found in the literature search for this thesis also conclude that no effect was seen 
between gabapentin and placebo (Aghighi et al., 2012). It is important to note that all studies 
on pharmacodynamics and efficacy of gabapentin in dogs are conducted on acute or 
inflammatory pain. Studies such as these are easier to control, evaluate and find cases for, but 
the indication for gabapentin in humans is neuropathic pain. It has been proven that gabapentin 
requires an upregulation of the VDCC-subunit to exert its main action, a mechanism which does 
not modulate acute, inflammatory pain. Therefore, gabapentin may well have effect for 
neuropathic pain in dogs, but the evidence to strengthen this is low to non-existent. The studies 
merely confirm that gabapentin does not relieve acute, inflammatory pain. The drug is being 
used empirically for neuropathic pain without proper studies based on evidence of the effect 
seen on these conditions in humans. Furthermore, in Aghighi et al. (2012) a low dose gabapentin 
and methadone were compared to solely methadone as analgesic protocols after intervertebral 
disc surgery. One alternative theory for the lack of apparent allodynia in the gabapentin groups 
in this study is that methadone has an inhibitory action on the NMDA receptor. This action 
results in an inhibitory effect on central sensitization (Gorman et al. 1997), which could 
influence these results. 
Future prospects 
Gabapentin has been established as an alternative for treatment of neuropathic pain conditions, 
but there are chronic conditions involving pain, such as cancer, where the origin is of both 
inflammatory and neuropathic character. There are also chronic pain conditions mainly 
characterized by inflammatory pain where a progression in severity may lead to a neuropathic 
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component. Treatment of these mixed pain conditions could, in theory, benefit from a drug such 
as gabapentin (Rahman & Dickensson, 2013). 
Although gabapentin is being increasingly prescribed to our pets the pharmacodynamics and 
efficacy have not been studied in these species. It has not been established whether the 
recommended therapeutic plasma concentration in humans can be extrapolated to dogs or other 
pets. This gives rise to a risk that a drug that could potentially treat chronic pain conditions, a 
field of medicine which lacks sufficient alternatives today, may be administered in a way that 
gives rise to suboptimal plasma concentrations in our pets. Therefore, more research is needed 
to determine the pharmacodynamics of gabapentin in various species. It should be recognized 
that gabapentin is a challenging drug to study adverse effects on in a clinical environment in 
our pets because of the scarce number of animals using the drug and the fact that it is most 
commonly used as a complementary drug incorporated in multimodal pain protocols.  Because 
of the potential benefits in treating otherwise untreatable pain conditions, it is of paramount 
importance to further investigate if gabapentin provides the same analgesic effect for dogs as 
seen in studies of humans. 
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APPENDIX 
Appendix 1. Questionnaire 
Hej!  
 
Mitt namn är Charlie Peck och jag skriver mitt examensarbete i veterinärmedicin vid Sveriges 
Lantbruksuniversitet (SLU), Uppsala.  
 
Du har fått den här enkäten för att du har/har haft en hund som behandlats med substansen 
gabapentin. Mitt examensarbete kretsar kring att öka kunskapen kring läkemedlets effekt och 
vilka eventuella biverkningar som kan ses hos hundar som behandlas med medicinen, samt om 
dessa biverkningar kan relateras till vilken dos hunden har fått. 
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Eftersom dagens forskning på hur gabapentin påverkar hundar är relativt begränsad behöver 
jag din hjälp för att få en överblick över hur gabapentin upplevs fungera i praktiken hos våra 
hundar. Jag är oerhört tacksam om du/ni tar er tid att svara på enkäten nedan och återsänder 
den i bifogat frankerat kuvert innan den 15/10 2017.  
 
Resultaten kommer att redovisas på gruppnivå och publiceras som ett examensarbete på 
Epsilon, SLU:s litteraturdatabas. Möjlighet finns att få läsa det slutgiltiga arbetet från och med 
januari 2018. 
 
Ingen utöver jag och min handledare Lena Olsén kommer gå igenom ditt djurs journaler och 
ingen övrig journalinformation kommer att användas utan ert godkännande.  
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Enkäten tar cirka 15 minuter att slutföra. 
 
Stort tack på förhand! 
 
 
Med vänlig hälsning, 
Charlie Peck 
Veterinärstudent år 6 
Sveriges Lantbruksuniversitet 
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Handledare: Lena Olsén 
Docent i Farmakologi 
Kontakt: lena.olsen@slu.se 
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Ditt namn: ______________________________ Hundens namn: _____________________________  
 
Datum:____________________________________________________________________________ 
 
1. Varför skrevs Gabapentin ut till just din hund? 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
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2. Vilken dos Gabapentin startade din hund på? 
 
___________________________________________________________________________ 
 
3. Trappades medicineringen upp succesivt? 
 
 Ja 
 Nej 
 
4. A) Hade din hund några tecken på biverkningar av Gabapentin? 
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 Ja 
 Nej 
              
              B) Om din hund hade biverkningar: Vad resulterade detta i? 
 
 Vi fortsatte ge Gabapentin i samma dos. 
 Vi sänkte dosen. 
 Vi slutade ge Gabapentin och bytte ej till annat läkemedel. 
 Vi slutade ge Gabapentin och bytte till ett annat läkemedel. Specificera vilket: 
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_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
 Biverkningarna upphörde. 
 Annat. Specificera:  
 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
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C) Om din hund hade biverkningar: När förekom dessa? 
 När läkemedlet började ges. 
 När dosen höjdes. Om ja, vid vilken dos?:  
 
_____________________________________________________________________ 
 Efter en längre tids behandling med samma dos. Om ja, efter hur lång tid?:  
 
_____________________________________________________________________ 
 Annat. Specificera:  
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_____________________________________________________________________ 
 
 
5. Fick din hund några andra läkemedel under tiden som Gabapentin gavs? 
 Ja. Specificera vilka:  
 
_____________________________________________________________________ 
 Nej 
 Vet ej 
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6. Hade Gabapentin önskad effekt för din hunds sjukdomssymtom? 
 Ja. På vilket sätt sågs förbättring?:  
 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
 Nej. Eventuell kommentar:  
 
_____________________________________________________________________ 
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7. Övriga kommentarer. Om kommentaren rör en specifik fråga, skriv frågans nummer 
nedan.: 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
40 
 
 
___________________________________________________________________________ 
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Tabellen nedan fylls i oavsett om biverkningar setts hos din hund eller ej. 
 
Under de två första veckorna av gabapentingiva, noterade du något av symtomen listade nedan? 
Markera även till vilken allvarlighetsgrad (1-5) biverkningen förekom. För varje symptom väljs 
en gradering enligt skalan nedan. 
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      Symptom    Gradering 
 Ej 
förekommit 
(1) 
Lindrigt 
(2) 
Måttligt (3) Kraftigt (4) Mycket 
kraftigt 
(5) 
Nervositet      
Skakningar      
Muskelryckningar/kramper      
Yrsel      
Nedstämdhet      
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Trötthet/utmattning      
Nedsatt kontaktbarhet/Distanserad      
Lugnare/Mindre orolig      
Rörelsestörningar (t.ex. snubblande gång eller 
sämre koordination) 
     
Upplevts ha nedsatt syn      
Ökad sömn      
Minskad sömn      
Klåda      
Hudförändringar/Utslag      
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Ökad aptit      
Nedsatt Aptit      
Ökat drickande/kissande      
Tecken på buksmärta (tittar sig/slickar sig mot 
buken, står i “bugande” ställning, krummande 
rygg etc.) 
     
Tecken på illamående (slickar sig om munnen, 
mindre intresserad av mat etc.) 
 
     
Kräkningar      
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Jag vill ta del av arbetet när det är färdigställt: 
Diarré      
Förstoppning      
Viktnedgång      
Viktuppgång      
Övriga (specificera och gradera från 1-5):  
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 Ja 
 Nej 
 
 
Tack för att du tagit dig tid att fylla i enkäten och därmed bidragit 
till ökad kunskap om läkemedlet gabapentin! 
 
 
 
 
 
 
